Research programme: Fas receptor antagonists - ONL TherapeuticsAlternative Names: Met12; ONL 1204; ONL101
Latest Information Update: 12 Feb 2016
At a glance
- Originator ONL Therapeutics
- Class Peptides; Small molecules
- Mechanism of Action CD95 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Age-related macular degeneration; Retinal detachment